Literature DB >> 25501114

Variant translocation partners of the anaplastic lymphoma kinase (ALK) gene in two cases of anaplastic large cell lymphoma, identified by inverse cDNA polymerase chain reaction.

Kayo Takeoka1, Atsuko Okumura, Gen Honjo, Hitoshi Ohno.   

Abstract

In anaplastic large cell lymphoma (ALCL), the anaplastic lymphoma kinase (ALK) gene is rearranged with diverse partners due to variant translocations/inversions. Case 1 was a 39-year-old man who developed multiple tumors in the mediastinum, psoas muscle, lung, and lymph nodes. A biopsy specimen of the inguinal node was effaced by large tumor cells expressing CD30, epithelial membrane antigen, and cytoplasmic ALK, which led to a diagnosis of ALK(+) ALCL. Case 2 was a 51-year-old man who was initially diagnosed with undifferentiated carcinoma. He developed multiple skin tumors eight years after his initial presentation, and was finally diagnosed with ALK(+) ALCL. He died of therapy-related acute myeloid leukemia. G-banding and fluorescence in situ hybridization using an ALK break-apart probe revealed the rearrangement of ALK and suggested variant translocation in both cases. We applied an inverse cDNA polymerase chain reaction (PCR) strategy to identify the partner of ALK. Nucleotide sequencing of the PCR products and a database search revealed that the sequences of ATIC in case 1 and TRAF1 in case 2 appeared to follow those of ALK. We subsequently confirmed ATIC-ALK and TRAF1-ALK fusions by reverse transcriptase PCR and nucleotide sequencing. We successfully determined the partner gene of ALK in two cases of ALK(+) ALCL. ATIC is the second most common partner of variant ALK rearrangements, while the TRAF1-ALK fusion gene was first reported in 2013, and this is the second reported case of ALK(+) ALCL carrying TRAF1-ALK.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25501114     DOI: 10.3960/jslrt.54.225

Source DB:  PubMed          Journal:  J Clin Exp Hematop        ISSN: 1346-4280


  4 in total

1.  Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.

Authors:  Jo-Anne van der Krogt; Marlies Vanden Bempt; Julio Finalet Ferreiro; Nicole Mentens; Kris Jacobs; Ursula Pluys; Kathleen Doms; Ellen Geerdens; Anne Uyttebroeck; Pascal Pierre; Lucienne Michaux; Timothy Devos; Peter Vandenberghe; Thomas Tousseyn; Jan Cools; Iwona Wlodarska
Journal:  Haematologica       Date:  2017-06-28       Impact factor: 9.941

2.  Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib.

Authors:  Thomas Lee Collier; Marc D Normandin; Nickeisha A Stephenson; Eli Livni; Steven H Liang; Dustin W Wooten; Shadi A Esfahani; Michael G Stabin; Umar Mahmood; Jianqing Chen; Wei Wang; Kevin Maresca; Rikki N Waterhouse; Georges El Fakhri; Paul Richardson; Neil Vasdev
Journal:  Nat Commun       Date:  2017-06-08       Impact factor: 14.919

3.  Diagnostic Capability of Next-Generation Sequencing Fusion Analysis in Identifying a Rare CASE of TRAF1-ALK-Associated Anaplastic Large Cell Lymphoma.

Authors:  Indu Agarwal; Linda Sabatini; Mir B Alikhan
Journal:  Front Oncol       Date:  2020-05-08       Impact factor: 6.244

Review 4.  Genetic Alterations of TRAF Proteins in Human Cancers.

Authors:  Sining Zhu; Juan Jin; Samantha Gokhale; Angeli M Lu; Haiyan Shan; Jianjun Feng; Ping Xie
Journal:  Front Immunol       Date:  2018-09-20       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.